%0 Journal Article
%T Continuation or deprescribing of proton pump inhibitors: A consult patient decision aid
%A Barbara Farrell
%A Cynthia Way
%A Lisa Richardson
%A Lise M. Bjerre
%A Peter Tugwell
%A Vivian Welch
%A Wade Thompson
%J Archive of "Canadian Pharmacists Journal : CPJ".
%D 2019
%R 10.1177/1715163518816719
%X Many patients continue on long-term proton pump inhibitor (PPI) therapy unnecessarily.1 Evidence-based guidance suggests attempting to reduce or stop PPIs in patients whose symptoms abate and have no indication for long-term use.2 Patients may therefore be faced with the decision to continue or reduce PPI use. Deprescribing is the planned, supervised dose reduction or stopping of a medication (for PPIs: lower dose or use ¡°on demand¡± [as needed]). Patients are generally open to discussing ongoing PPI use; however, the decision to continue or reduce PPI use depends on preferences and values.3 Patients would like to be part of such discussions and planning surrounding ongoing PPI use.3,4 Thus, a structured tool to guide such a discussion would be helpful in clinical practice
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346337/